Dr. Marra Francis Joins Genece Health as Chief Medical Officer
April 03 2024 - 8:00AM
Genece Health, a molecular testing company focused on improving
cancer detection for lung, breast, ovarian and other cancers, today
announced that Marra Francis, MD, FACOG, has joined the company as
its chief medical officer.
Dr. Francis is a board-certified Obstetrician
and Gynecologist with over 23 years of clinical practice and 18
years of commercial leadership roles across the diagnostics and
biotech sectors. She is also currently a member of the MIT Catalyst
Faculty. Most recently, Dr. Francis was an advisor to Droplet
Biosciences and to Exai Bio, where she built their respective
target product profiles ahead of Droplet’s first product launch and
Exai’s clinical validation study. At Delphi, she led an early
access program for their flagship commercial test. Dr. Francis’
past experience also includes serving as head of medical affairs
for women's health of Sema4 (now GeneDx); as executive medical
director of EverlyWell; and as chief medical officer of Aspira
Women's Health. Earlier in her career, she served as both vice
chair and chair of the Department of Obstetrics and Gynecology at
Memorial Hermann Hospital of the Woodlands. Dr. Francis holds a
medical degree from the University of Connecticut Health Center and
a bachelor of arts degree in biology from Occidental College.
Dr. Marra Francis named as Genece Health CMO
“We are delighted to have Marra join our team at
a very exciting time for Genece,” said Greg Gosch, CEO of
Genece Heath. “Marra’s clinical expertise in women’s health and
oncology will be pivotal in the advancement of our clinical studies
and bringing our liquid biopsy and deep-learning AI technology to
market. Our goal is to empower physicians with critical insights
they need to make informed decisions and improve patient care.
Marra will be instrumental in driving key milestones to ultimately
help change the way cancer is detected.”
About Genece HealthGenece
leverages a proprietary liquid biopsy and deep-learning AI
technology for early cancer detection. The Company was founded in
2022 through a strategic partnership with GC Genome, the genomics
arm of GC Corporation, a leading life sciences company in South
Korea. Genece focuses on the acute need for targeted screening and
detection tools to support decision-making when a mass or lump is
detected through imaging, empowering physicians to make informed
decisions and improve care. The Company’s initial applications
include high-mortality and women’s health cancers. For more
information, visit genecehealth.com or follow Genece
on LinkedIn.
Investor Contact:investors@genecehealth.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7c648163-47e0-4823-b27d-e8426f22ed15